TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2019.1654993
Abstract: ABSTRACT Introduction: Type 2 diabetes is a complex metabolic disorder defined by hyperglycemia which occurs because of impaired insulin secretion and sensitivity. There is an ongoing need to develop novel therapies that are effective and… read more here.
Keywords: treatment type; activator potential; type diabetes; glucokinase activator ... See more keywords
Effect of Renal Impairment on the Pharmacokinetics and Safety of Dorzagliatin, a Novel Dual-acting Glucokinase Activator.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and translational science"
DOI: 10.1111/cts.13174
Abstract: Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI)… read more here.
Keywords: dorzagliatin novel; glucokinase; effect renal; glucokinase activator ... See more keywords
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14697
Abstract: To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D). read more here.
Keywords: insulin withdrawal; ketoacidosis insulin; glucokinase activator; hepatoselective glucokinase ... See more keywords
A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14909
Abstract: To report the rationale for using PB‐201, a partial glucokinase activator (GKA), for a Phase 3 study (NCT05102149) assessing its efficacy and safety in a Chinese population and to describe the design of this GKA… read more here.
Keywords: glucokinase activator; study; placebo; phase ... See more keywords
Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0265761
Abstract: Glucokinase activators are regarded as potent candidates for diabetes treatment, however, in clinical studies on patients with type 2 diabetes, a diminishing efficacy was observed after chronic treatment with them. The mechanism of this reduction… read more here.
Keywords: chronic treatment; efficacy; glucokinase activator; diminished efficacy ... See more keywords
Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2017.00169
Abstract: Previously, compound 19e, a novel heteroaryl-containing benzamide derivative, was identified as a potent glucokinase activator (GKA) and showed a glucose-lowering effect in diabetic mice. In this study, the anti-apoptotic actions of 19e were evaluated in… read more here.
Keywords: cytokine induced; beta; compound 19e; glucokinase activator ... See more keywords